PACT pharma press releases
Jan 10, 2020
PACT Pharma Raises $75M in Oversubscribed Series C Financing to Develop Fully Personalized NeoTCR-T Cell Therapies for Patients with Cancer
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2020 /PRNewswire/ — PACT Pharma, in pursuit of its vision to eradicate solid tumors using transformational, first-in-class fully personalized NeoTCR-T cell therapies, today announced that it has closed an oversubscribed $75 million Series C financing. This round, led by Vida Ventures, a next generation life science venture firm with industry-leading experience in the cell and gene therapy, also included current investors of PACT.
Nov 21, 2019
PACT Pharma Appoints Uneek Mehra as Chief Financial Officer
South San Francisco, Calif. — November 21, 2019 – PACT Pharma announced today that Uneek Mehra joined the company as Chief Financial Officer. Mr. Mehra has more than twenty years of global finance experience. He joins from Proteus Digital Health, where he served as Chief Financial Officer. Mr. Mehra has deep experience across pharmaceuticals, technology and financial services, through senior roles at Novartis, IBM and Citibank.
Oct 02, 2019
PACT Pharma Appoints Tim Moore as President and Chief Technical Officer
The pace of innovation and development for CAR-T therapies over the past several years has increased dramatically. There are only a handful of people at the center of the action,” said Alex Franzusoff, CEO of PACT Pharma. “Tim, among this select group, has successfully led his team to bring these complex medicines to market, and his experience with CAR-T therapies at Kite will be invaluable as PACT seeks to establish new frontiers defining personalized cell therapies for patients with solid tumors.
Jul 21, 2019
Personalized gene-edited immune cell therapy for patients with solid cancers: New data establishes approach for verifying patient-specific cancer mutation targets
PACT Pharma, a leader in the fields of cancer immunology and cell therapy in collaboration with a team at UCLA, presented new data demonstrating for the first time the ability to identify mutation targets unique to each person’s cancer and verify the cancer specificity of multiple cloned T cell receptors. Each patient’s cancer has a private signature of mutations, creating an opportunity to develop fully personalized immune therapies that have the potential to eradicate tumor cells.